Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Inclusion Criteria:

- Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):

- Aggressive natural killer (NK)-cell leukemia

- Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)

- Angioimmunoblastic T-cell lymphoma

- Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)

- PTCL, not otherwise specified (NOS)

- T/NK-cell lymphoma, nasal type

- Enteropathy-type intestinal lymphoma

- Hepatosplenic T-cell lymphoma

- Subcutaneous panniculitis T-cell lymphoma

- Transformed mycosis fungoides (at diagnosis of transformation)

- T-cell prolymphocytic leukemia (T-PLL)

- Cutaneous gamma/delta (γ/δ) T-cell lymphoma

- Cutaneous aggressive CD8+ T-cell lymphoma

- Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)

- Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative
disorders of childhood)

- Other T-Cell lymphomas that are not listed in the Exclusion Criteria

- Patient gives written informed consent

Exclusion Criteria:

- Patient has other T- or NK-cell malignancies including:

- Precursor T/NK neoplasms

- T-cell large granular lymphocytic leukemia

- Mycosis fungoides, other than transformed mycosis fungoides

- Sézary syndrome

- Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis